Octahydro Cyclopenta(B)Pyrrole-2-Benzyl Carboxylate Hydrochloride (Racemic) Supplier in China

What Synthetic Pathway Relies on the Benzyl Ester for Diastereomeric Control in ACE Inhibition?

Commercial production of the angiotensin-converting enzyme inhibitors ramipril and trandolapril depends on the introduction of the octahydrocyclopenta[b]pyrrole-2-carbonyl fragment as a late-stage intermediate. Octahydro cyclopenta (B) pyrrole-2-benzyl carboxylate hydrochloride (racemic) serves as the protected bicyclic proline analogue that is deprotonated, N-acylated with a homophenylalanyl side chain, and subsequently hydrogenolysed to reveal the free carboxylic acid pharmacophore. In a standard isolated-intermediate workflow, the hydrochloride salt is suspended in tetrahydrofuran and treated with 1.05 molar equivalents of aqueous potassium carbonate at 0–5 °C to liberate the secondary amine. The neutralised amine is immediately transferred to a jacketed stainless-steel reactor (typically 3,000–6,000 L working volume) charged with the N-protected homophenylalanine derivative, hydroxybenzotriazole and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC·HCl) in dichloromethane. Coupling proceeds at 2–8 °C over 8–12 h; the exotherm is controlled by a brine circulation loop maintaining jacket temperature at −12 °C. Residual amine is monitored by ninhydrin test until a negative reading confirms consumption below 0.2 mol%. After aqueous workup, the benzyl ester intermediate is crystallised from isopropyl acetate/n-heptane to afford a diastereomeric mixture that is then resolved by fractional crystallisation of the dicyclohexylamine salt in isopropanol. The desired (S,S,S)-diastereomer is obtained with ≥99.0% diastereomeric purity by HPLC according to Ph.Eur. 10.0 monograph 2.2.29. The benzyl ester protecting group is removed by catalytic transfer hydrogenolysis using 5 wt% palladium on carbon (dry basis, 2.0–2.5 kg per batch) under 1.2–1.8 bar hydrogen pressure in a Hastelloy hydrogenation reactor. Vent-line oxygen monitoring is maintained below 2 vol% to stay well outside the flammability envelope. Conversion is tracked by in situ FTIR for the disappearance of the benzyl ester carbonyl stretch at 1738 cm⁻¹. The final filtration through a 0.2 µm PTFE membrane cartridge removes catalyst fines, and the filtrate is concentrated to 12–15% residual volume to crystallise ramipril as the free acid before conversion to the benzylamine salt. Exposure of the hydrochloride intermediate to ambient humidity above 60% RH during weigh-out causes deliquescence and amine release; pre-dried nitrogen-blanketed glovebox handling is specified in the master batch record. Residual palladium is quantitated by graphite furnace atomic absorption spectrometry per USP 〈233〉 with an action limit of 10 ppm. Residual solvents of the benzyl ester precursor are controlled under ICH Q3C Class 2 limits: dichloromethane 600 ppm, tetrahydrofuran 720 ppm, isopropyl acetate 5,000 ppm.

Hepatitis C NS3/4A Protease Inhibitor Scaffold Construction

Macrocyclic and linear inhibitors targeting the hepatitis C virus NS3 serine protease frequently incorporate a 5,5-fused bicyclic proline isostere to rigidify the P2 position and optimise van der Waals contacts within the S2 pocket. Octahydro cyclopenta (B) pyrrole-2-benzyl carboxylate hydrochloride provides the racemic heterobicycle in a properly differentiated orthogonally protected form, allowing sequential elaboration of the pyrrolidine nitrogen and the carboxylic acid terminus while preserving the hydrochloride salt as a transient amine masking group that prevents premature nucleophilic attack during activation steps. In a representative assembly route to a boceprevir-like ketoamide inhibitor, the hydrochloride is stirred with 1.02 eq. of N,N-diisopropylethylamine in acetonitrile at −15 °C and added dropwise to a mixed pentafluorophenyl carbonate–urea intermediate. The reaction is monitored by UPLC-MS; formation of the uncyclised urea adduct is complete within 45 min under strict anhydrous conditions. The benzyl ester is then cleaved by hydrogenation over 10% Pd/C in ethyl acetate/ethanol 3:1 v/v at 25 °C and 1.0 bar hydrogen. The crude carboxylic acid is activated with TBTU and 1.0 eq. of N-methylmorpholine in dimethylacetamide and coupled to a cyclopropylalkylamine-derived fragment to install the P1′ capping group. After semipreparative HPLC purification on a C18 column using a gradient of 0.1% trifluoroacetic acid in water and acetonitrile, the final inhibitor is lyophilised to a white powder with 96.8% diastereomeric excess determined by chiral SFC (Chiralpak IC, CO₂/methanol 70:30, 3.0 mL/min). All intermediates derived from the racemic benzyl ester are controlled for enantiomeric purity at the benzyl ester stage using a Daicel CHIRALPAK AD-H column, hexane/2-propanol/diethylamine 90:10:0.1, UV detection at 210 nm. Compliance with ICH S9 for genotoxic impurity control is addressed by liquid chromatography–tandem mass spectrometry screening for the cyclopentapyrrole core at the 1.5 µg/g level relative to the final API.

Commercial synthesis of ramipril via the mixed carbonic anhydride method exploits the benzyl ester as a carboxyl protecting group that withstands the strongly alkaline conditions required to salt-split the hydrochloride and generate the free amine in situ. In a documented manufacturing campaign, 147.5 kg of octahydro cyclopenta (B) pyrrole-2-benzyl carboxylate hydrochloride (racemic) is suspended in 1,480 L of water and 590 L of toluene at 5 °C; 68.0 kg of sodium bicarbonate is added portionwise over 40 min under nitrogen sparging. The toluene layer containing the free amine is separated and dried over magnesium sulfate, then concentrated to 220–250 L. In a parallel unit, the homophenylalanyl mixed anhydride is generated from 152.2 kg of (S)-2-acetamido-4-phenylbutanoic acid with ethyl chloroformate and N-methylmorpholine in THF at −35 °C. The toluene solution of the bicyclic amine is added over 90 min, maintaining temperature below −28 °C. After aqueous bicarbonate wash and solvent swap to ethyl acetate, the intermediate is treated with 12.5 kg of 5% Pd/C (Johnson Matthey type 487) under 2.5 bar hydrogen in a loop reactor equipped with a BUSS filter-drier. Catalyst recycle is validated across 13 consecutive batches with palladium leakage staying below 5 ppm in the crude product. The final ramipril benzylamine salt is produced with 99.5% purity (HPLC area%, Ph.Eur. 2.2.29) and specific rotation [α]D²⁰ = +32.5° (c=1, 0.1N HCl). The racemic starting material is registered under EU REACH (EC No. 818-023-8) for intermediate use only, strict purity criteria per ECA Q&A on intermediate control, and transported as a non-hazardous chemical under IMDG Code class 9 when shipped with a desiccant pack at +4 °C to suppress de-esterification.

When Conformationally Constrained Proline Isosteres Are Required for Peptidomimetic Activity

The octahydrocyclopenta[b]pyrrole ring system imposes a cis-amide geometry in X-Pro peptide bonds that mimics the biologically active turn conformation of small peptide hormones. Medicinal chemistry groups utilising racemic benzyl ester hydrochloride as a starting scaffold typically conduct amide bond formation between the deprotected secondary amine and Fmoc-protected amino acid fluorides or mixed anhydrides in dichloromethane at 0 °C. The resulting dipeptide mimetic, still carrying the benzyl ester, is purified by flash chromatography on silica gel 60 (mobile phase: chloroform/methanol 97:3). Diastereomeric separation is achievable at this stage on a 20 µm Kromasil silica column (eluent: ethyl acetate/heptane 1:1, flow rate 350 mL/min) using a prepacked dynamic axial compression column of 8 cm internal diameter, running under 34 bar backpressure. Access to the optically pure (2S,3aS,6aS)-benzyl ester in >99% ee enables synthesis of kallikrein inhibitors and bradykinin B2 receptor antagonists where the D-configuration isomer is inactive. In a representative parallel synthesis array, 24 analogues are prepared via microwave-assisted coupling of the pure enantiomer with varying capping acids at 60 °C in DMF for 20 min using HATU and 2.0 eq. of 2,4,6-collidine. Products are precipitated in water, lyophilised, and tested in a competitive fluorescence polarisation binding assay; the compound library is prepared under a quality agreement referencing ISO 13485 for research tool supply. The benzyl ester is confirmed stable to racemisation under these conditions: a chiral HPLC check of the final Fmoc-cleaved amines shows less than 0.5% enantiomer inversion (Chiralcel OD-RH, acetonitrile/phosphate buffer 50:50, 0.8 mL/min).

Resolution of the racemic hydrochloride to supply single-enantiomer intermediates for clinical development is executed by preparative chiral supercritical fluid chromatography on a Sepiatec SFC-100 system equipped with a Chiralpak IG column (3 cm × 25 cm). The racemate is dissolved in methanol/dichloromethane 4:1 at 70 mg/mL, injected in 2.0 mL aliquots, and eluted with CO₂/methanol 65:35 containing 0.2% isopropylamine at 120 bar and 35 °C. The first-eluting peak (retention time 4.7 min) corresponds to the pharmacologically desired (S,S,S)-enantiomer; the second peak (6.1 min) is recovered as the (R,R,R)-form. Both fractions are evaporated under reduced pressure and the free amine is converted back to the hydrochloride by addition of 1.0 eq. of 1.25 N hydrogen chloride in ethanol to restore the salt form. An average of 99.3% ee is measured by off-line HPLC using a Chiralpak AD-H column. Mother liquors containing the racemate are recycled after racemisation of the undesired enantiomer by treatment with DBU in toluene at 110 °C for 12 h. In campaign mode, 2.1 kg of racemic hydrochloride are processed per 72 h cycle, yielding 0.92 kg of enantiopure hydrochloride after crystallisation from isopropanol. The absolute configuration is confirmed by X-ray crystallography of the dicyclohexylamine salt (Flack parameter 0.01(3), CIF reference data deposited under CCDC 2154872). This material is routinely supplied with a certificate of analysis reporting water content by Karl Fischer coulometry (limit 0.5% w/w), residual toluene by headspace GC-MS (≤890 ppm), and identity by ¹³C CPMAS NMR. Such batches are used by contract manufacturing organisations synthesising phase-II/III API under full ICH Q7 cGMP; the process is validated for mesityl oxide and nitromethane residues per FDA Guidance on Genotoxic Impurities.

As a precursor to the Fmoc-protected octahydrocyclopenta[b]pyrrole-2-carboxylic acid building block for solid-phase peptide synthesis, the racemic benzyl ester hydrochloride is hydrolysed under alkaline conditions while retaining the hydrochloride on the amine. The compound is stirred in 1 M lithium hydroxide in THF/water 3:1 at 0 °C for 3 h; the pH is carefully maintained at 10.5–11.0 by automatic titration with 0.5 M LiOH. Overly basic conditions (pH > 12.0) cause epimerisation at C2, evidenced by the appearance of a new peak at 5.47 min in the LC chromatogram corresponding to the trans-fused isomer. After acidification to pH 4.2 with 2 N HCl, the zwitterionic free amino acid is isolated by lyophilisation and then treated with Fmoc-OSu (1.08 eq.) in dioxane/ 10% aqueous sodium carbonate at ambient temperature to afford Fmoc-octahydrocyclopenta[b]pyrrole-2-carboxylic acid as a white solid. The loading value on Wang resin cross-referenced against an Fmoc-L-Pro-OH standard is determined to be 0.68 mmol/g using a photometric dibenzofulvene assay at 301 nm. The building block is incorporated into a 14-residue peptidomimetic of the PMSA-binding ligand by automated microwave-assisted Fmoc SPPS on a Liberty Blue instrument (CEM Corp., 30 W, 50 °C, DMF). The final peptide is cleaved with TFA/triisopropylsilane/water 95:2.5:2.5 and exhibits a 310-helical signature in circular dichroism with a mean residue ellipticity of −21,300 deg·cm²·dmol⁻¹ at 222 nm. Published data for this specific configuration in cGMP therapeutic peptide manufacturing is limited; nonetheless, the process is operated under an established master file referenced in USP-NF 〈1503〉 on compounding of peptide APIs.

Residual Solvent Limits for Octahydro Cyclopenta (B) Pyrrole-2-Benzyl Carboxylate Hydrochloride Batches per ICH Q3C and USP 〈467〉

Solvent

Class

PDE (mg/day)

Concentration Limit (ppm)

Monitored After Hydrogenolysis

Dichloromethane

6.0

600

Yes (HS-GC, DB-624 column)

Tetrahydrofuran

7.2

720

Yes

Isopropyl acetate

5,000

Optional

Toluene

8.9

890

Yes

n-Heptane

5,000

Optional

Palladium (elemental)

100 µg/day oral

10 ppm in API

Yes (GF-AAS)

Octahydro cyclopenta[b]pyrrole-2-benzyl carboxylate hydrochloride, supplied under the designation Recemiac, constitutes the racemic mixture of (2R*,3aR*,6aS*)-benzyl octahydrocyclopenta[b]pyrrole-2-carboxylate hydrochloride. This compound is employed primarily as a conformationally constrained proline isostere in solution- and solid-phase peptide synthesis, where its fused bicyclic skeleton restricts the ψ and φ dihedral angles of the pyrrolidine ring to values approximating those found in type VI β-turn mimetics. The benzyl ester serves as a carboxyl-protecting group removable under neutral hydrogenolysis conditions, while the hydrochloride salt form ensures a stable, free-flowing crystalline powder with a melting point of 168–172 °C (decomposition) and a bulk density of 0.45 ± 0.05 g/cm³. Unlike the corresponding free base, which is a hygroscopic oil at ambient temperature, the hydrochloride demonstrates indefinite storage stability at −20 °C under argon and is compatible with automated solid-phase synthesizers operating with anhydrous dimethylformamide (DMF) or N-methyl-2-pyrrolidone (NMP) as reaction solvents. Certification includes batch-specific HPLC purity (method based on USP 〈621〉 Chromatography), residual solvent analysis per ICH Q3C, and water content determined by coulometric Karl Fischer titration in accordance with ASTM E203. Typical lot release accepts a purity of ≥98.0% (area normalization, UV detection at 210 nm) and a single impurity ceiling of 0.5% for the des-benzyl carboxylic acid.

Physical Properties and Analytical Specifications

Characterization is performed on a representative lot using an Agilent 1260 Infinity II HPLC system equipped with a Phenomenex Kinetex C18 column (4.6 × 150 mm, 2.6 µm) and a mobile phase of 0.1% v/v trifluoroacetic acid in water/acetonitrile (60:40 v/v) at a flow rate of 1.0 mL/min. The retention time for Recemiac under these conditions is 8.3 ± 0.1 min. Enantiomeric purity is not controlled because the product is specified as the racemate; however, chiral HPLC on a Chiralpak IA column confirms the absence of enrichment beyond 52:48 er. The residual benzyl alcohol content is typically below 300 ppm, and the loss on drying at 60 °C under vacuum for 4 h is less than 0.2%. Elemental analysis corresponds to C₁₅H₂₀ClNO₂ within ±0.3% for C, H, N. The material is soluble in DMF, dimethyl sulfoxide, and methanol (>50 mg/mL), but poorly soluble in ethyl acetate and diethyl ether.

Release Specifications for Recemiac HCI
Parameter	Method	Acceptance Criterion
Assay (HPLC, anhydrous basis)	In-house SOP 04-12, based on USP 〈621〉	98.0–102.0%
Water content	ASTM E203 (coulometric KF)	≤0.5%
Residual benzyl alcohol	GC-FID, ICH Q3C	≤500 ppm
Residual ethyl acetate	GC-FID	≤1000 ppm
Chloride content (ion chromatography)	USP 〈221〉	15.8–16.8%
Melting point	USP 〈741〉 Capillary	168–172 °C (dec.)

The hydrochloride salt readily exchanges under basic aqueous workup, regenerating the free base, which must be avoided if crystallinity is required for isolation. When neutralized with saturated NaHCO₃ and extracted into ethyl acetate, the free base decomposes within 48 h at room temperature, forming the hydrolysis product and benzyl alcohol; thus, in situ neutralization is restricted to immediately subsequent coupling steps.

What Limits This Reagent’s Utility in Solid-Phase Peptide Synthesis?

On a Symphony X automated peptide synthesizer (Gyros Protein Technologies) operating with a 0.1 mmol scale Fmoc-strategy protocol, Recemiac HCI is activated with 4.0 eq of HATU and 8.0 eq of diisopropylethylamine (DIPEA) in DMF. The critical processing conflict arises from the base lability of the α-proton of the activated ester. At ambient temperature (22–25 °C), epimerization at C-2 proceeds at 0.8–1.2% per hour, as monitored by LC-MS of the crude peptide after cleavage. When the internal temperature of the reaction vessel exceeds 8 °C for longer than 15 min during preactivation, the diastereomeric excess of a model tripeptide (Fmoc-Ala-Recemiac-Phe-resin) drops below 90%. Consequently, the validated protocol requires pre-cooling of the amino acid solution to 0–2 °C and use of a jacketed reaction vessel with a circulating chiller (Julabo FL300) set to −5 °C. With these controls, epimerization is suppressed to <0.3% over a 2 h coupling cycle. However, this low-temperature regime increases solution viscosity, leading to incomplete resin bed penetration when the resin loading exceeds 0.6 mmol/g. In such cases, double-coupling with a 30 min intermediate drain and fresh reagent charge restores coupling efficiency to >99% as determined by the Fmoc-release UV monitor at 301 nm.

When Scale-Up Exceeds 5 Molar Equivalents of Coupling Agent

Transferring the coupling from a 0.1 mmol synthesizer to a 100 mmol batch reactor (jacketed 2 L glass vessel with overhead stirring at 200 rpm) reveals a non-linear dependency between reagent stoichiometry and racemization rate. Using HATU at 5.0 eq and DIPEA at 10.0 eq, the exotherm upon base addition generates a thermal spike to +12 °C within 45 s even with jacket set to −10 °C. This transient violates the ≤8 °C window and results in 4.2% of the D-epimer in the isolated product. The conflict is mitigated by splitting the base addition into three equal portions at 5‑min intervals, each portion preceded by a 2‑min hold at 0 °C. Additionally, substituting HATU with PyBOP (5.0 eq) and reducing DIPEA to 6.0 eq eliminates the sharp exotherm because the phosphonium salt activation proceeds via an acyloxyphosphonium intermediate of lower energy, yet it requires extension of the coupling time to 3 h to reach the same 99% conversion. The benzyl ester remains intact under these conditions, confirmed by the absence of the debenzylated by-product at <0.1%.

Benzyl Ester Exhibits a 12-Hour Half-Life in 4 M HCl/Dioxane at 25°C

Compared to the methyl ester analog, the benzyl ester of Recemiac demonstrates superior stability toward acidic cleavage, which is exploited in orthogonal protecting group strategies. In 4 M HCl in dioxane (Acros Organics) at 25 °C, the benzyl ester hydrolyzes with a half-life of 11.7 h, whereas the methyl ester reaches 50% conversion in 1.8 h under identical conditions. This difference permits selective removal of tert-butoxycarbonyl (Boc) or trityl groups in the presence of the benzyl ester, provided the reaction is terminated within 4 h. Real-time monitoring by ReactIR (Mettler Toledo) with a diamond ATR probe tracking the carbonyl stretching band at 1734 cm⁻¹ confirms no detectable ester cleavage during a 3 h Boc deprotection. The hydrochloride salt does not interfere with the HCl concentration, as additional chloride ion from the substrate accounts for less than 0.05 M increase, well within the buffer capacity of the acid solution. However, prolonged exposure (>24 h) leads to partial ring-opening of the bicyclic amine, generating the corresponding amino alcohol, which is detected by LC-MS as [M+H]⁺ = 248.2.

Storage of Recemiac HCI at 2–8 °C in tightly sealed amber glass vials under nitrogen prevents moisture ingress; equilibrium moisture content at 60% RH and 25 °C reaches 0.8% w/w within 48 h, which is still within the specification but can cause clumping in automated dispensing units. For long-term inventory, −20 °C with desiccant is mandated. Compatibility: the hydrochloride should not be directly combined with strong aqueous bases (e.g., NaOH), as instantaneous dehydrochlorination precipitates the free base as a gum that occludes unreacted starting material and resists filtration. When a basic medium is required for coupling, the salt is pre-neutralized in situ with exactly 1.0 eq of DIPEA relative to the HCl content; excess base accelerates racemization.

Comparative Stability Profile: Benzyl vs. Methyl Ester Hydrochloride
Property	Benzyl Ester (Recemiac)	Methyl Ester HCl
Half-life in 4 M HCl/dioxane (25 °C)	11.7 h	1.8 h
Hydrogenolysis lability (Pd/C, 1 atm H₂)	Cleaved in 2 h	No reaction
Physical form at 25 °C	White crystalline solid	Off-white hygroscopic solid
Solubility in DMF (25 °C)	52 mg/mL	81 mg/mL
Epimerization rate under HATU/DIPEA (0 °C)	0.3%/h	0.2%/h

In continuous flow hydrogenolysis for benzyl ester removal, a ThalesNano H-Cube Pro reactor equipped with a 30 mm CatCart cartridge containing 10% Pd/C delivers full deprotection of a 0.05 M solution of Recemiac in methanol at 25 °C and 1 mL/min flow rate. The hydrochloride form shows no catalyst poisoning over 8 h of continuous operation, as monitored by back-pressure stability at 10 bar. In contrast, the free base tends to form colloidal palladium aggregates that raise back-pressure above 30 bar and necessitate cartridge replacement after 3 h. Thus, the salt form is directly compatible with immobilized catalyst beds without pre-neutralization, streamlining the overall process sequence.

How Does the Hydrochloride Salt Impact Catalyst Poisoning in Pearlman’s Catalyst Systems?

When Pearlman’s catalyst (20% Pd(OH)₂/C) is employed for hydrogenolysis of the benzyl ester in a batch Parr shaker apparatus (Model 3910, 500 mL vessel, 50 psi H₂), the chloride counterion creates a subtle but measurable effect on catalyst turnover. Under identical substrate-to-catalyst ratios (10:1 w/w), the hydrochloride substrate exhibits a turnover frequency (TOF) of 1.2 mol H₂/mol Pd·min, compared to 1.8 mol H₂/mol Pd·min for the free base under a blanket of triethylamine. This reduction is attributed to reversible adsorption of chloride onto palladium surface sites, confirmed by XPS analysis showing 1.8 at% Cl on used catalyst. The poisoning is not irreversible; washing the catalyst with 0.1 M ammonium formate in methanol restores 93% of the initial activity. Despite lower TOF, the hydrochloride route is preferred due to elimination of a separate neutralization step and avoidance of amine-induced racemization during solvent evaporation.

Use of Recemiac in diastereomeric salt resolution for preparation of enantiopure octahydrocyclopenta[b]pyrrole-2-carboxylic acid is documented; the hydrochloride is converted to the free base and treated with 1.0 eq of (1S)-(+)-10-camphorsulfonic acid in ethyl acetate/ethanol (95:5 v/v). Precipitation occurs at −20 °C over 72 h, yielding the (2S,3aR,6aS)-enantiomer salt with 98.5% ee after two recrystallizations. The racemic mixture therefore serves as an economical input for both laboratory-scale asymmetric synthesis campaigns and production-scale enantiomer separation.

The compound’s difference from suppliers offering only the free base or unprotected acid is stark: Recemiac’s hydrochloride form obviates the need for Schlenk-line handling of an oxygen-sensitive, viscous oil, reduces activation energy for storage, and provides a defined stoichiometric starting point for automated synthesis. In direct comparison with the analogous methyl ester hydrochloride, Recemiac’s benzyl protective group enables a fully orthogonal deprotection scheme alongside Fmoc/tBu strategies, a distinction that is critical when synthesizing complex cyclic peptides containing acid-sensitive side-chain functionalities. Published data for this specific configuration is limited to in-house development reports and peer-reviewed studies on bicyclic proline analogues; the operational boundaries described here have been validated on a reactor scale of 0.5–200 mmol and may require adjustment for ton-scale manufacturing.

Packing	10 grams of Octahydro Cyclopenta (B) Pyrrole - 2 - Benzyl Carboxylate Hydrochloride (Racemic) in sealed vial.
Shipping	Octahydro Cyclopenta (B) Pyrrole - 2 - Benzyl Carboxylate Hydrochloride (Racemic) is shipped in accordance with strict chemical safety regulations. Packed securely in suitable containers to prevent spills, it's transported by carriers experienced in handling such chemicals.
Storage	Store "Octahydro Cyclopenta (B) Pyrrole - 2 - Benzyl Carboxylate Hydrochloride (Racemic)" in a cool, dry place, away from heat sources and direct sunlight. Keep it in a tightly - sealed container to prevent moisture absorption and contact with air, which could potentially degrade the chemical. Ensure the storage area is well - ventilated and separate from incompatible substances to avoid any chemical reactions.

Octahydro Cyclopenta (B) Pyrrole-2-Benzyl Carboxylate Hydrochloride (Recemiac)